ClinicalTrials.gg
Not yet recruitingNCT06763991Updated May 16, 2025

Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery

An interventional study of Two-stage connection and One-stage connection in Microtia, Outcome Assessment and RCT, sponsored by Sichuan Provincial People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Sichuan Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
6 Years to 30 Years
Sex
All
01

Study summary

Eligible patients will be admitted from the outpatient clinic to complete the relevant examinations after admission(Preoperative routine examination and chest CT). The baseline parameters will be registered when admitted to hospital, including case number, diagnosis, sex, age, height, weight, and underlying medical conditions. Patients have at least 12 hours to consider participation in the study and will be given the opportunity to ask questions about the study. Written informed consent will be obtained by the surgical resident or the surgeon after admission to the hospital.

Randomization will be done by relevant member . After inclusion, patients will be allocated to one of the two study groups (First-stage Connection or Second-stage Connection) using an online randomization program. The perioperative care will be the same for all included patients.Surgery will be performed by experienced surgeons, with non-expanded ear reconstruction using autologous rib cartilage. The surgery normally comprises two stages. After each surgery, details and duration of the surgery will be documented. For each stage of surgery, patients are scheduled for visits about 3-6 months. In addition, after the total surgery, patients are to fill out 'Glasgow Benefit Inventory' and 'Patient and Observer Scar Assessment Scale'.

02

Conditions studied

  • Microtia
  • Outcome Assessment
  • RCT
  • Surgery Related Complications Rate
  • Treatment Outcome
  • Reconstruction

Browse trials for

03

In context

Congenital Microtia

33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.

This study's planned enrollment of 78 is above the median of 34 across 23 interventional studies indexed under Congenital Microtia.

Browse Congenital Microtia studies →

Lead sponsor

Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All consecutive patients between 6 and 30 years with a congenital concha-microtia8, admitted to our hospital are potentially eligible, and enrollment in the study will be based on the following criteria.

  1. Patients were fully informed about the purpose, modalities and risks associated with this study, signed an form and were willing to be followed up.
  2. Contrast-enhanced computed tomography (CT) scan shows he or she has 3.Patients can tolerate general anesthesia without severe chronic organic or mental illness.

Exclusion criteria

Exclusion Criteria:

  1. Patients combined with other ear diseases such as ear fistula, titis media, etc.
  2. Patients receive other unrelated ear surgeries during the study
  3. Skin in the surgical area with infection, ulceration, and scarring.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    First-stage Connection

    After obtaining written informed consent, eligible patients will be randomized with a 1:1 allocation using an online randomization module. A random number will be assigned sequentially to make sure that every patient will be randomly allocated into two groups (Accepting First-stage Connection and Second-stage Connection).

    Procedure: One-stage connection

  • Experimental
    Two-stage connection

    After obtaining written informed consent, eligible patients will be randomized with a 1:1 allocation using an online randomization module. A random number will be assigned sequentially to make sure that every patient will be randomly allocated into two groups (Accepting One-stage connection and Two-stage connection).

    Procedure: Two-stage connection

Interventions

  • ProcedureTwo-stage connection

    Two-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear during the second stage surgery of ear reconstruction. An intact cartilage framework is embedded in skin pocket in the first stage, hence, in the second stage of surgery, parts of the cartilage framework that has already survived will be shaved off to ensure the firm combination between the residual era cartilage and grafted costal cartilage.

  • ProcedureOne-stage connection

    One-stage connection refers to a procedure that connecting and incorporating the cartilage framework with the residual ear in the first stage surgery of ear reconstruction. In one-stage surgery, the cartilage framework is connected with the residual ear (non-deformed, unexcluded part) to form a smooth and complete ear subunit structure. In this way, it is necessary to trim the excess postauricular skin, which may pose a greater risk of blood supply. After the first stage of surgery, the overall appearance of surgical ear is already roughly similar to that of a normal ear.

06

What researchers measure

Primary outcomes

  1. Grade-A healing

    Grade-A healing is defined as optimal wound alignment, epidermal integrity, and tight subcutaneous tissue junctions, with no significant inflammatory response or complications during recovery, and the stitches can be removed within 10 days after the operation.

    Time frame: For each stage of surgery, patients are scheduled for visits about 3-6 months.

Secondary outcomes

  1. complication rates

    Incidence of infection, hematoma, flap necrosis, skin necrosis, and cartilage scaffold exposure

    Time frame: For each stage of surgery, patients are scheduled for visits about 3-6 months.

  2. Scar score

    The Patient and Observer Scar Assessment Scale (POSAS) is a validated and applicable tool for scar evaluation. There are two numeric scales of POSAS, one for patients and another for observers. Each of items receives a score from 1 to 10. A score of 1 represents normal skin and 10 represents the worst scar imaginable. To add the scores of each item, a total score of the observer scale ranges from 5 to 50, and a patient scale ranges from 6 to 60. The lowest scores, 5 and 6, respectively, reflect normal skin. The higher the scores, the worse the scar.

    Time frame: 3-6 months after the total ear reconstruction surgery

  3. Patients' satisfaction score

    To evaluate patients' satisfaction of the final result after surgery, we use Glasgow benefit inventory(GBI) as a evaluated tool. GBI comprises 18 items. Each item is scored using the Likert 5-level scoring scale. The GBI total score can range from -100 (maximum adverse effect) through 0 (no effect) to 100 (maximum benefit). In addition, subscores can be calculated: a general subscore, a social support score and a physical health score.

    Time frame: 3-6 months after the total ear reconstruction surgery

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Feb 2027, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 8, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Feb 20, 2027
CompletionEst.
Feb 20, 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06763991
Lead sponsor
Sichuan Provincial People's Hospital
Responsible party
Xinjie Zhang (Principal investigator, Sichuan Provincial People's Hospital) — Principal investigator
First posted
Jan 8, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
May 16, 2025

Study contacts

xinjie zhang
Contact
zzzhangxinjie@163.com
86-15881116743

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion